Mazahir Alimohamed
Stock Analyst at Oppenheimer
(0.33)
# 4,501
Out of 5,051 analysts
18
Total ratings
33.3%
Success rate
-17.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $100 | $74.40 | +34.41% | 4 | Oct 2, 2026 | |
| CNTB Connect Biopharma Holdings | Rated: Buy | $8 → $5 | $0.9057 | +452.06% | 2 | Sep 22, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 → $40 | $19.60 | +104.08% | 3 | Sep 22, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 | $3.26 | +574.85% | 3 | Aug 12, 2026 | |
| IKT Inhibikase Therapeutics | Reiterated: Buy | $5 | $1.85 | +171.00% | 2 | Aug 12, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $9 | $1.59 | +466.04% | 3 | Jul 20, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $38.45 | +32.64% | 1 | Jul 9, 2026 |
Tarsus Pharmaceuticals
Oct 2, 2026
Reiterated: Buy
Price Target: $100
Current: $74.40
Upside: +34.41%
Connect Biopharma Holdings
Sep 22, 2026
Rated: Buy
Price Target: $8 → $5
Current: $0.9057
Upside: +452.06%
Tyra Biosciences
Sep 22, 2026
Reiterated: Buy
Price Target: $50 → $40
Current: $19.60
Upside: +104.08%
BridgeBio Oncology Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $22
Current: $3.26
Upside: +574.85%
Inhibikase Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $5
Current: $1.85
Upside: +171.00%
InflaRx
Jul 20, 2026
Reiterated: Buy
Price Target: $9
Current: $1.59
Upside: +466.04%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $38.45
Upside: +32.64%